In this survey we will be reviewing the stocks that make up the North American Marijuana Index. In Part 1, we’ll look at Canopy Growth Corp. (OTCPK:TWMJF), GW pharmaceuticals (NASDAQ:GWPH), Axim Biotechnologies Inc. (OTCQB:AXIM), and United Cannabis Corp. (OTCQB:CNAB).
Aphria Inc. is the newest weed company to graduate to the TSX. The stock has been faring better than its peers, Canopy Growth Corp. and Aurora Cannabis Inc. over the past few months.
Beyond the legal issues, the problem for investors is that the industry is filled with small publicly traded companies that are risky bets at best, and outright fraudulent at worst.
MyDx (OTCQB:MYDX) Stock Chart Technical Analysis for March 24, 2017.
Insys Therapeutics’ stock rose on good news — but not tremendously so.
Legal marijuana flat-Earthers, like U.S. Attorney General Jeff Sessions, have tried many methods to discredit breakthroughs in medical cannabis, but these efforts at discrediting cannabis stop at the U.S. border.
Major cannabis stock indices have been falling for three consecutive weeks, ever since White House Press Secretary Sean Spicer suggested the federal government would enforce federal law in states where recreational weed has been legalized.
Marijuana has quickly become the next “can’t miss” investing idea for investors across North America. Despite this huge potential market, people are reluctant to put any of their cash into this market
There are a number of big institutions, including mutual funds, pension funds, and investment banks, that use the TSX Composite and its sub-indices as performance benchmarks for their portfolios. The addition of Canopy to the index will introduce some new dimensions to the index’s performance.
Canopy Growth Corporation (TSX:WEED) is being added to the influential S&P/TSX Composite Index in another milestone for Canada’s fledgling marijuana industry.
There’s been something in the air on the ASX recently and it’s inducing some strange behaviour in traders betting on higher and higher share prices in some emerging companies.
The California Cannabis Business Expo wound down on March 8, closing with two panels at the Marijuana Investor Summit: one featuring the CEOs of three U.S. based firms active in the cannabis space; the other featuring four business and financial executives from Canada, who could speak to the state of the same industry in a very different legal and cultural context.
The cannabis industry’s excitement is building as the California takes steps towards establishing its legal recreational market. This week Los Angeles voters approved Measure M to create regulations for adult-use marijuana, thus setting up the city to steal the title of marijuana capital from Denver.
Publicly-traded marijuana companies had a rough week but got a bounce Thursday following news of raids at the Cannabis Culture dispensary chain owned by Marc and Jodie Emery.
The investing community demands regular performance updates in the form of financial reports. While the need to impress investors is creating pressure for the infant marijuana industry, are the companies fairly reporting performance?
A newly released survey from the independent Quinnipiac University really demonstrates just how strongly the American public wants to see marijuana legalized, and how certain they are that state’s rights should prevail.
Insys Therapeutics announced a compassionate-use program for its cannabis-based epilepsy drug, igniting optimism that the company is continuing to develop marijuana medicine.
Bets on marijuana companies helped an Australian manager soar 145 percent last year to become the world’s best-performing hedge fund.
Investors are becoming more and more impressed with the job CEO Terry Booth and his team are doing at Aurora Cannabis Inc. After posting strong Q2 results and closing a C$75 million financing, there’s a lot to like with company.
A federal crackdown on marijuana isn’t bad news for all marijuana stocks.
While President Donald Trump vowed on his campaign trail to let states decide the fate of marijuana legalization, recent comments by the Trump Administration seem to negate his campaign promise and have created a ripple effect in the public cannabis markets.
In the last trading session, the stock price of Medical Marijuana Inc (OTCMKTS:MJNA) declined more than 8% to close the day at $0.112. The decline came at a share volume of 24.74 million compared to average share volume of 17.32 million.
Shares of Canadian and U.S. marijuana producers fell Friday after the Trump administration suggested a crackdown on recreational marijuana may be in the works.
Investors in cannabis companies had an eventful 2016 with the approval of recreational marijuana usage in the states of California, Massachusetts, Maine, and Nevada providing a boost to all sorts of marijuana stocks. Of particular note, shares of Corbus Pharmaceuticals (NASDAQ: CRBP) posted a whopping 600% gain in 2016 following positive phase 2 data.
It certainly has been a great day for pot stocks on the ASX. This morning Federal Health Minister Greg Hunt announced that the government would allow medical marijuana companies to distribute cannabis oils and medications in Australia within the next couple of months.
Canopy Growth Corp. has garnered the most attention and established itself as the market leader; however, there is another company in the Canadian marijuana industry that could emerge as a potential winner.
Since seeing all the buzz and craze these companies are causing in the marketplace, we’ve been hot on the trail of companies tied to the cannabis sector. The budding marijuana industry has spawned several high flying stocks lately, like Mentor Capital Inc.
Over the next five years, the U.S. marijuana market could be worth tens of billions of dollars, and according to GreenWave Advisors, LLC, these five states could move the needle most for marijuana companies. Learn just how big the marijuana market may be in California, Washington, Pennsylvania, Colorado, and Michigan in 2021.
The cannabis industry is expected to reach $50 billion in size by 2026, according to Cowen & Co., making it one of the fastest growing industries in the world. Investors have taken a growing interest in the industry as legalization has spread across North America. Here are three subsets of the cannabis industry that investors may want to consider for the best risk-adjusted returns.
Marijuana stocks are riding high as the stock index is up for the eighth consecutive week.
Investors are incredibly excited about Canopy Growth Corporation. But we’re now looking at a situation where the stock has increased quite aggressively thanks mostly to the belief that the future is bright. And there are still many investors sitting on the sidelines wondering if they should consider this company.
“We are continuing to see Canadian companies invest in or acquire assets in U.S. cannabis markets […] looking to take advantage of increased demand abroad,” a Viridian Capital analyst says.
Roto-Gro International, a Canadian cannabis-tech company has been admitted to the ASX, and has become the latest player to join the list of cannabis based companies on the ASX.
Canopy Growth Corporation’s generating eye-popping returns for investors. However, there are risks ahead that could rein in some investor optimism.
Marijuana prices are falling. Could marijuana stock prices drop soon, too?
On the face of it, 2017 may be the year to jump into the marijuana market to get a piece of what looks to be promising growth over the next few years.
As of Wednesday, traders on the Toronto Stock Exchange can buy and sell “WEED.”
While there are a number of big issues and industries that could be impacted by the Gorsuch nomination (should he be confirmed), the marijuana industry and marijuana stocks have to be wondering how this nomination could impact them.
A federal court in Boston last week entered judgments against a publicly traded company purportedly serving medical marijuana businesses over allegations that it defrauded investors by lying about the company’s true owner.
Chris Blake, Senior Portfolio Manager, TD Wealth, explains what investors need to know before buying marijuana stocks.
Florida is undeniably behind the curve when it comes to passing pro-pot legislation, but the Sunshine State did make up some ground in November, when voters legalized medical marijuana in the state. How big could the medical marijuana market be in Florida for marijuana stocks?
Forward-thinking investors are already plotting seven-figure weed windfalls with the top pot stocks from every ecosystem. You see, there’s more to the marijuana industry than just selling cannabis. There are a lot of ways to profit from legal recreational and medical marijuana sales.
Investing in cannabis stocks is being called the “gold rush” of the 21st century. That’s because legal marijuana sales in North America climbed to $6.7 billion in 2016.
Marijuana Index Review for 2017, United States and Canada Medical Cannabis Market website and it’s different features for stocks, and my input on investing.
Cannabis Science Inc (OTC:CBIS) — Stock Chart Technical Analysis for Jan. 23, 2017.
Marijuana stocks may be in for a bumpy ride this year.
The market for marijuana is exploding as Americans overwhelmingly embrace legalization. Analysts are projecting tens of billions of dollars in future marijuana sales, making this an intriguing market for investors.
Marijuana sales has the potential to greatly add to government’s treasury as well, and it will be immensely helpful in medical fields. Nowadays, it is also easier for banks for provide services for legal marijuana businesses.
Real estate is the next big catalyst for marijuana stocks in 2017, as more voters demand legalized recreational and medical cannabis in their states.
A comprehensive study slams many of the alleged benefits of marijuana and points to serious negative effects. What will the impact of this study be for marijuana stocks?